Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Neumora Therapeutics Inc’s stock clocked out at $0.79, up 6.31% from its previous closing price of $0.74. In other words, the price has increased by $6.31 from its previous closing price. On the day, 0.62 million shares were traded.
Ratios:
To gain a deeper understanding of NMRA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.98 and its Current Ratio is at 8.98. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Stifel Downgraded its Buy to Hold on March 07, 2025, whereas the target price for the stock was revised from $6 to $2.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Henry Gosebruch bought 15,000 shares for $1.43 per share.
BERNS PAUL L sold 13,871 shares of NMRA for $23,468 on Feb 18 ’25. The insider now owns 7,405,004 shares after completing the transaction at $1.69 per share. On Feb 18 ’25, another insider, Milligan Michael Lee, who serves as the insider of the company, sold 1,978 shares for $1.69 each. As a result, the insider received 3,351 and left with 22,470 shares of the company.
Stock Price History:
Over the past 52 weeks, NMRA has reached a high of $17.19, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is 4.35%, while the 200-Day Moving Average is calculated to be -87.56%.
Shares Statistics:
A total of 161.75M shares are outstanding, with a floating share count of 65.21M. Insiders hold about 59.69% of the company’s shares, while institutions hold 28.38% stake in the company.
